Health and Wellness
CNY HealthAbout
Important information
- Advertising Review:BBB sent correspondence to CNY Health on April 8, April 15, and May 6, 2025 requesting more information about advertised claims featured in advertising and marketing materials to include the website https://cnyhealthpllc.com/. To date, the business has not responded to our request.
According to BBB’s Code of Advertising #34. Claimed Results
Claims relating to performance, energy savings, safety, efficacy or results for a product or service should be based on recent and competent testing or other objective data.
The website features health-benefit and structure-function claims attributed to advertised services. These claims would require competent and reliable scientific substantiation from robust clinical trials on humans. It is BBB’s understanding that to advertise these claims would classify the products as drugs which would require FDA approval.
To follow are the questions that BBB asked and/or concerns that BBB found with the advertising on the website https://cnyhealthpllc.com/:
1. Does the business only prescribe compounded peptides/hormones/drugs?
There does not appear to be an FDA disclaimer on the website stating that the products prescribed are not FDA approved. BBB requested that this information be disclosed in the advertising and marketing materials. In example, “Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.”, or “Compounded drugs are not FDA approved, which means the agency does not verify their safety, effectiveness or quality before they are marketed.” This information should be disclosed in a clear and conspicuous location in all marketing materials.
https://cnyhealthpllc.com/index.php/provider/
The website states, “All of our staff”, “working with our team”
2. BBB asked how many people are on the staff / team and if any of them provide services that may require licensing.
The website states, “Her additional training includes medical weight loss, men’s testosterone replacement therapy and women’s bioidentical hormone replacement therapy, specifically BHRT pellet procedures.”
3. BBB asked if the additional training was provided by an agency or school that provides certifications or diplomas once training is completedand if so, can a copy of those be provided for BBB's records.
https://cnyhealthpllc.com/index.php/mens-testosterone/
The website states, “Initial comprehensive evaluation is $200 and includes first month’s membership.”
4. BBB asked what is meant by membership.
https://cnyhealthpllc.com/index.php/medical-weight-loss/
The website states, “We truly understand the benefits and know how to manage the side effects of semaglutide and tirzepatide. We have relationships with several reputable compounding pharmacies that provide the product for us.”
5. BBB requested information about the fact that semaglutide and tirzepatide have been removed from the FDA shortage list, if CNY Health plans on prescribing Ozempic, Wegovy, and Zepbound to their patients.
6. BBB asked that since the compounded versions may no longer be available, will that affect the cost of the SEMAGLUTIDE WEIGHT LOSS PROGRAM and TIRZEPATIDE WITH B12 as advertised on the website.
https://cnyhealthpllc.com/index.php/peptide-therapy-and-injectables/
BBB advised of the following peptides advertised on CNY Health's websitee that BBB has found warnings for from the FDA. The information that BBB referenced with regard to each peptide can be found in this FDA publication that states the content is current as of September 27, 2024: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Under Healing and recovery
BPC 157
BBB has found information from the FDA stating, “Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.”
TB 500
BBB has found information that TB 500 is also known as Thymosin beta-4, fragment (LKKTETQ) and information from the FDA states, “Compounded drugs containing thymosin Beta-4, Fragment (LKKTETQ) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities. FDA has not identified any human exposure data drug products containing Thymosin Beta-4, Fragment. FDA lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans.”
CJC-1295
BBB has found information from the FDA stating, “Compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization. FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”
Ipamorelin
BBB has found information from the FDA stating, “Compounded drugs containing Ipamorelin acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Ipamorelin acetate also contains unnatural amino acids, which add to the complexity of peptide characterization. A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility. FDA has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans via those routes.”
Under Sexual Health and Anti-aging
Epithalon
BBB has found information from the FDA stating, “Compounded drugs containing epitalon may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has not identified safety-related information regarding epitalon for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.”
GHK-Cu
BBB has found information from the FDA stating, “Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations.”
Under Improved Fitness and Overall Health
LL-37 & Thymosin (stacked)
BBB has found information from the FDA stating, “Compounded drugs containing cathelicidin LL-37 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA lacks sufficient safety-related information regarding cathelicidin LL-37 to know whether the drug would cause harm when administered to humans. Nonclinical research findings suggest detrimental effects on male reproduction and that this drug can be protumorigenic in some tissues.”
Which Thymosin are you referring to?
AOD 9604
BBB has found information from the FDA stating, “Compounded drugs containing AOD-9604 may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has identified no, or only limited, safety-related information. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans. FDA has also identified serious adverse events that may be associated with AOD-9604, though causality is not clear.”
MOTs-C
BBB has found information from the FDA stating, “Compounded drugs containing MOTs-C may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has not identified, any human exposure data on drug products containing MOTs-C administered via any route of administration. FDA lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans.”
CJC-1295
BBB has found information from the FDA stating, “Compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to for peptide-related impurities and API characterization. FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction. Available clinical data are limited.”
Ipamorelin
BBB has found information from the FDA stating, “Compounded drugs containing Ipamorelin acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities. Ipamorelin acetate also contains unnatural amino acids, which add to the complexity of peptide characterization. A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility. FDA has not identified safety-related information regarding ipamorelin acetate via certain other injectable routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans via those routes.”
7. BBB asked if the business is aware of these warnings and how these concerns are addressed with the patients of CNY Health. BBB requested that the information from the FDA be provided in CNY Health's marketing materials.
BBB Business Profiles may not be reproduced for sales or promotional purposes.
BBB Business Profiles are provided solely to assist you in exercising your own best judgment. BBB asks third parties who publish complaints, reviews and/or responses on this website to affirm that the information provided is accurate. However, BBB does not verify the accuracy of information provided by third parties, and does not guarantee the accuracy of any information in Business Profiles.
When considering complaint information, please take into account the company's size and volume of transactions, and understand that the nature of complaints and a firm's responses to them are often more important than the number of complaints.
BBB Business Profiles generally cover a three-year reporting period, except for customer reviews. Customer reviews posted prior to July 5, 2024, will no longer be published when they reach three years from their submission date. Customer reviews posted on/after July 5, 2024, will be published indefinitely unless otherwise voluntarily retracted by the user who submitted the content, or BBB no longer believes the review is authentic. BBB Business Profiles are subject to change at any time. If you choose to do business with this company, please let them know that you checked their record with BBB.
As a matter of policy, BBB does not endorse any product, service or business. Businesses are under no obligation to seek BBB accreditation, and some businesses are not accredited because they have not sought BBB accreditation. BBB charges a fee for BBB Accreditation. This fee supports BBB's efforts to fulfill its mission of advancing marketplace trust.